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Aims: Tacrolimus is a critical dose drug and to avoid under- and overexposure, thera-
peutic drug monitoring is standard practice. However, rejection and drug-related toxic-
ity occur despite whole-blood tacrolimus pre-dose concentrations ([Tac]blood) being on
target. Monitoring tacrolimus concentrations at the target site (within peripheral blood
mononuclear cells; [Tac]cells) may better correlate with drug-efficacy. The aim of this
study was to (1) investigate the relationship between [Tac]blood and [Tac]cells, (2) identify
factors affecting the tacrolimus distribution in cells and whole-blood, and (3) study the
relationship between [Tac]cells and clinical outcomes after kidney transplantation.
Methods: A total of 175 renal transplant recipients were prospectively followed.
[Tac]blood and [Tac]cells were determined at Months 3, 6 and 12 post-transplantation.
Patients were genotyped for ABCB1 1199G>A and 3435C>T, CYP3A4 15389C>T,
and CYP3A5 6986G>A. Data on rejection and tacrolimus-related nephrotoxicity and
post-transplant diabetes mellitus were collected.
Results: Correlations between [Tac]blood and [Tac]cells were moderate to poor
(Spearman's r = 0.31; r = 0.41; r = 0.61 at Months 3, 6 and 12, respectively). The
[Tac]cells/[Tac]blood ratio was stable over time in most patients (median intra-patient vari-
ability 39.0%; range 3.5%–173.2%). Age, albumin and haematocrit correlated with the
[Tac]cells/[Tac]blood ratio. CYP3A5 and CYP3A4 genotype combined affected both dose-
corrected [Tac]blood and [Tac]cells. ABCB1 was not significantly related to tacrolimus
distribution. Neither [Tac]blood nor [Tac]cells correlated with clinical outcomes.
Conclusions: The correlation between [Tac]blood and [Tac]cells is poor. Age, albumin
and haematocrit correlate with the [Tac]cells/[Tac]blood ratio, whereas genetic varia-
tion in ABCB1, CYP3A4 and CYP3A5 do not. Neither [Tac]blood nor [Tac]cells correlated
with clinical outcomes.
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1 | INTRODUCTION
Although transplant recipients undoubtedly benefit from therapeu-
tic drug monitoring (TDM), a considerable number of patients
experience acute rejection, despite tacrolimus whole-blood pre-
dose concentrations ([Tac]blood) being within the therapeutic
range.1–3 Long-term allograft failure is also an important problem,
with 3–5% of kidney allografts being lost annually after the first
transplant year, mainly as a result of rejection and tacrolimus-
related nephrotoxicity.4–6
The immunosuppressive effect of tacrolimus is mediated through
the inhibition of calcineurin within lymphocytes. In clinical practice,
however, whole-blood is the matrix used for TDM. In whole-blood,
tacrolimus is distributed extensively into erythrocytes, which do not
contribute to alloreactivity. This may explain why multiple studies
could not find a correlation between [Tac]blood and rejection in solid
organ transplant recipients.3,7–9 A better correlation with drug effi-
cacy can be expected from direct quantification of the tacrolimus con-
centration at the target site. Tacrolimus measurement in peripheral-
blood mononuclear blood cells (PBMCs; [Tac]cells), which represent a
blood compartment enriched with lymphocytes, has been proposed as
a superior method to monitor tacrolimus treatment.10–12 In liver trans-
plant recipients, [Tac]cells significantly correlated with both the devel-
opment and the severity of rejection.8 Moreover, previous studies
reported poor to moderate correlations between [Tac]cells and [Tac]-
blood, indicating that [Tac]blood does not always reflect the concentra-
tion at the target site.8,11,13–17
This poor correlation may reflect the activity of the efflux
transporter protein ABCB1 in mononuclear cell membranes. Differ-
ences in ABCB1 activity may result in differences in intra-
lymphocytic tacrolimus accumulation and tacrolimus pharma-
codynamics.18–20 In case of a high ABCB1 activity, both [Tac]cells
and the [Tac]cells/[Tac]blood ratio are expected to be low. In a study
by Capron et al., different ABCB1 single-nucleotide polymorphisms
(SNPs) were associated with reduced ABCB1 activity and higher
[Tac]cells, while having no effect on [Tac]blood in 96 renal transplant
recipients.18
Tacrolimus metabolism is mediated by the cytochrome P450
enzymes CYP3A4 and CYP3A5.21 The CYP3A5*3 variant allele has
been associated consistently with low CYP3A5 enzymatic activity and
a low tacrolimus dose requirement as compared to the CYP3A5*1
allele.22–24 SNPs in the CYP3A4 gene have also been associated with
tacrolimus pharmacokinetics.24,25 However, little is known about the
influence of CYP3A4 and CYP3A5 genotype on [Tac]cells. Capron et al.
observed significantly lower dose-adjusted [Tac]cells and [Tac]blood in
CYP3A5 expressers18 and Tron et al. did not find any association
between CYP3A4 and CYP3A5 genotype and either [Tac]cells or
[Tac]blood.
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In this study, the relationship between [Tac]cells and [Tac]blood in
kidney transplant recipients was investigated, as well as the influence
of genetic variability in the ABCB1, CYP3A4 and CYP3A5 genes on
[Tac]cells. A total of 175 renal transplant recipients were followed pro-
spectively and blood and PBMCs were collected at 3, 6 and 12 months
post-transplantation in order to study which matrix correlated best
with the occurrence of allograft rejection or tacrolimus-related
toxicity.
2 | METHODS
2.1 | Patients and sample collection
This study is a post hoc analysis and includes renal allograft recipients
who participated in a randomized, controlled clinical trial that com-
pared the efficacy of standard, bodyweight-based tacrolimus dosing
with CYP3A5 genotype-based tacrolimus dosing.26 In this trial,
patients were followed until the third postoperative month. For the
present study, sample collection (but not the collection of clinical data)
was extended up until Month 12.
Only patients with an available [Tac]cells and [Tac]blood 3 months
post-transplantation were included in this analysis. Patients with a
[Tac]cells with a red level >2 (see paragraph on [Tac]cells measurement
below), were excluded from the analysis. The study was approved by
the institutional review board of the Erasmus MC, University Medical
Center, Rotterdam (Medical Ethical Review Board number 2010-080).
All patients provided written informed consent for the study.
What is already known about this subject
• Lymphocytes are the target cells of the immunosuppres-
sant tacrolimus.
• The whole-blood concentration is the standard matrix for
therapeutic drug monitoring of tacrolimus.
• Tacrolimus whole-blood concentrations do not optimally
predict rejection and toxicity.
• The intra-lymphocytic tacrolimus concentration may cor-
relate better with clinical outcomes than whole-blood
concentrations.
What this study adds
• The correlation between peripheral blood mononuclear
cells and whole-blood tacrolimus concentrations is poor.
• Age, albumin and haematocrit are correlated with the
PBMC/whole-blood tacrolimus concentration ratio.
• Single-nucleotide polymorphisms in ABCB1, CYP3A4 or
CYP3A5 do not explain inter-patient variability in
tacrolimus distribution.
• The PBMC tacrolimus concentration is not associated
with rejection nor tacrolimus-related toxicity in the first 3
months after kidney transplantation.
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Patients received basiliximab induction therapy followed by triple
immunosuppression consisting of tacrolimus, mycophenolate mofetil
(MMF) and prednisolone, as described by Shuker et al.26 Patients were
randomized to receive a tacrolimus starting dose (Prograft®; Astellas
Pharma, Leiden, The Netherlands) twice daily based on either
bodyweight alone or a combination of CYP3A5 genotype plus
bodyweight. After the measurement of the first tacrolimus pre-dose
concentration on the third postoperative day (the first steady state
concentration), routine TDM was performed aiming for a target [Tac]-
blood of 10.0–15.0 ng/mL (week 1–2), 8.0–12.0 ng/mL (week 3–4),
and 5.0–10.0 ng/mL (after week 4) post-transplantation. For further
details regarding the immunosuppressive therapy, the reader is
referred to Shuker et al.26
2.2 | End points
The correlation between [Tac]blood and [Tac]cells was studied at 3, 6
and 12 months post-transplantation. The [Tac]cells/[Tac]blood ratio was
evaluated over time and the intra- and inter-patient variability of this
ratio are described. Covariate factors affecting this ratio were investi-
gated. Age, gender, haematocrit, serum albumin, serum creatinine,
ABCB1 genotype (wildtype vs. one allele variant vs. >one allele variant),
and CYP3A genotype (extensive vs. intermediate vs. poor metabolizers;
see below for more information on categorization) genotype were
evaluated as potential predictors. Also, the influence of pharmaco-
genetic variability in ABCB1 1199G>A, ABCB1 3435C>T, CYP3A4 and
CYP3A5 genotype on both [Tac]cells and [Tac]blood was investigated.
Finally, the relationship between the tacrolimus distribution and rejec-
tion and tacrolimus-related nephrotoxicity was evaluated.
2.3 | Rejection and tacrolimus-related toxicity
Biopsy-proven acute rejection (BPAR) was registered up until the third
postoperative month. Renal biopsies were performed for cause only
(no protocol biopsies) and were reviewed in a blinded fashion by two
independent pathologists and were graded according to the 2013
Banff classification of renal allograft rejection.27 Data on the presence
of post-transplant diabetes mellitus (PTDM) and tacrolimus-induced
nephrotoxicity were collected, as these events may be associated with
tacrolimus treatment. PTDM was defined as the use of glucose-
lowering medical therapy up until Month 3 after transplantation in a
patient not needing such treatment before transplantation.
Tacrolimus-related nephrotoxicity was defined as any ≥15% increase
of serum creatinine with a return to baseline after tacrolimus dose
reduction and after exclusion of other causes of renal transplant func-
tion deterioration.26 The estimated glomerular filtration rate (eGFR)
was calculated using the abbreviated MDRD study equation.28
2.4 | Whole-blood tacrolimus concentration
measurement
[Tac]blood was determined by two immunoassays: the antibody-
conjugated magnetic immunoassay (ACMIA) on a Dimension platform
(Siemens Healthcare, N.V., The Hague, The Netherlands) and the
enzyme multiplied immunoassay technique (EMIT; Siemens
Healthcare N.V.). In the first two years of the trial, [Tac]blood was mea-
sured exclusively by the ACMIA, after which measurements were per-
formed exclusively by the EMIT.26 ACMIA and EMIT immunoassays
demonstrated a high correlation (r = 0.97).26
2.5 | PBMC tacrolimus concentration
measurement
PBMCs were isolated from whole-blood pre-dose samples at Months
3, 6 and 12 post-transplantation, using a Ficoll separation technique.
The whole procedure was performed at room temperature. Cells were
counted (Sysmex XOP-300 cell counter), resuspended in PBS, snap
frozen in liquid nitrogen and stored until analysis at −80C in aliquots
of 1×106 cells per vial. To determine the presence of erythrocytes,
which could affect the measured tacrolimus concentration, the red-
ness of the cell pellet after PBMC isolation was rated on a scale from
0 to 8 by visual inspection (Figure S1 in the Supporting Information).
Samples with a red level above 2, were excluded from this study.
[Tac]cells were measured using a LC–MS/MS method, as described
previously.29,30
2.6 | Genotyping
DNA for the genotyping of CYP3A5*3 6986G>A (rs776746) was
extracted from peripheral-blood leukocytes by use of the Blood
DNA kit (Qiagen, Courtaboeuf, France). Genotyping was performed
using TaqMan Assay reagents for allelic discrimination (Applied Bio-
systems, Courtaboeuf, France) with a 7900 Applied Biosystems
thermal cycler as previously described.22,26,31 Genotyping of the
ABCB1 1199G>A (rs2229109), ABCB1 3435C>T (rs1045642) and
CYP3A4*22 15389C>T (rs35599367) alleles was performed using
TaqMan Assay reagents for allelic discrimination (San Diego, USA)
with a 7900 Applied Biosystems thermal cycler.22,31 All genotypings
were performed according to standard laboratory procedures in an
ISO15189 certified laboratory.
2.7 | Statistical analysis
All analyses were performed using R (Version 3.5.3).32 Categorical var-
iables are described as number of cases with proportions. Continuous
variables with a non-parametric distribution are described as median
with interquartile range (IQR). The Mann–Whitney U and the Kruskal-
Wallis test (for multiple groups) were used to compare non-parametric
variables. Spearman's correlation coefficient was used to determine
correlations between non-parametric variables. After a significant
result from the Kruskal-Wallis test, post hoc tests were performed
using a pairwise Mann–Whitney U-test with Bonferroni correction.
The Friedman test was used to compare non-parametric paired data
of multiple groups. Intra-patient variability was calculated for each
patient with complete data on the [Tac]cells/[Tac]blood ratio by the fol-
lowing formula: coefficient of variation (CV) %CV = Xsd/Xmean×100.
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Here, Xsd represents the standard deviation, and Xmean the mean of
the [Tac]cells/[Tac]blood ratios of Months 3, 6 and 12. The inter-patient
variability was calculated at Months 3, 6 and 12 with the following
formula: inter-patient variability % = Xtsd/Xtmean×100, where Xtsd and
Xtmean represent the standard deviation and the mean of the
[Tac]cells/[Tac]blood ratios at a certain time point. For the combined
CYP3A4 and CYP3A5 analysis, patients were categorized as poor,
intermediate and extensive metabolizers as proposed by Elens et al.33
For the combined analysis of the ABCB1 genotype, patients were cat-
egorized as ‘wildtype’ if they had no variant alleles (ABCB1 3435CC
and ABCB1 1199GG), as ‘one variant allele’ if they had one variant
allele (either ABCB1 3435 T or ABCB1 1199A), and as ‘>one variant
allele’ if they had more than one variant allele at the ABCB1 3435
and 1199 positions together. After the removal of an outlier (Cooks
distance >10), a multiple linear regression analysis was performed
to assess the contribution of covariates on the [Tac]cells/[Tac]blood
ratio. A logistic regression analysis was performed to assess the
relationship between the [Tac]cells/[Tac]blood ratio and clinical out-
comes, which included BPAR, drug-related nephrotoxicity
and PTDM.
2.8 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to PHARMA-
COLOGY, and are permanently archived in the Concise Guide to
PHARMACOLOGY 2019/20.34,35
3 | RESULTS
3.1 | Baseline characteristics
A total of 175 renal transplant recipients were included in this analy-
sis. Of the 237 patients included in the original trial by Shuker et al.,26
61 patients were excluded, based on: no available [Tac]cells (n = 36) or
[Tac]blood (n = 16) at Month 3 post-transplantation, or a red level
above 2 (see paragraph on [Tac]cells measurement; n = 9; Figure S2 in
the Supporting Information). One patient was excluded from the anal-
ysis because he was considered an outlier (Cooks distance > 10).
Table 1 summarizes the baseline characteristics.
3.2 | Relationship between whole-blood and
PBMC tacrolimus concentrations
Tacrolimus concentrations were measured at Month 3 (n = 175), 6
(n = 130) and 12 (n = 54) post-transplantation. The median [Tac]blood
decreased from 7.5 ng/mL (IQR 6.1–9.2) at Month 3, to 6.6 ng/mL
(IQR 5.6–8.2) and 5.9 ng/mL (IQR 4.3–7.7) at Months 6 and
12, respectively (Table S1 in the Supporting Information). The median
[Tac]cells also decreased from 26.5 pg/10
6 cells (IQR 18.8–37.0) at
Month 3, to 23.8 pg/106 cells (IQR 16.5–33.4) and 20.8 pg/106 cells
(IQR 12.5–31.4) at Months 6 and 12, respectively.
The correlations between [Tac]cells and [Tac]blood at Months 3, 6
and 12 post-transplantation were poor to moderate with Spearman's
correlation coefficients of r = 0.31, r = 0.41 and r = 0.61, respectively
(Figures 1A–C).
3.3 | The PBMC to whole-blood tacrolimus
concentration ratio over time
Next, the evolution of the [Tac]cells/[Tac]blood ratio over time was
investigated (Figure 2A and B). The median [Tac]cells/[Tac]blood ratio
was 3.5 (IQR 2.4–5.4) at Month 3, 3.5 (IQR 2.4–5.1) at Month 6 and
3.6 (2.5–4.7) at Month 12 post-transplantation (Table S1 in
Supporting Information). For patients with an available [Tac]cells at all
time points (n = 45), the [Tac]cells/[Tac]blood ratio did not change signif-
icantly over time (P = 0.71). The median intra-patient variability of the
[Tac]cells/[Tac]blood ratio in these patients was 39.0% and ranged from
3.5% to 173.2%. The inter-patient variability was higher, with 51.8%,
82.0% and 60.5% at Months 3, 6 and 12, respectively. The variability
in the [Tac]cells/[Tac]blood ratio of the 15 patients with the highest
intra-patient variability could not be explained by a change in
haematocrit or albumin (data not shown). In two patients the high
intra-patient variability in the [Tac]cells/[Tac]blood ratio could be
explained by a [Tac]cells under the limit of quantification, causing a
high ratio.
3.4 | Relationship between tacrolimus
concentrations and genotypes
Allelic frequencies of ABCB1, CYP3A5 and CYP3A4 are depicted in
Table S2 in the Supporting Information. The ABCB1 3435C>T,
CYP3A5 and CYP3A4 SNPs were in Hardy–Weinberg equilibrium (all
P > 0.05), but ABCB1 1199G>A genotype was not (P = 0.005491).
However, only two patients were homozygous for the variant allele
(1199AA), and with expected counts below five, the chi-square
approximation may be incorrect.
3.4.1 | ABCB1
At all time points, no significant difference in the [Tac]cells/[Tac]blood
ratio was observed between patients with different ABCB1 genotypes
(for both ABCB1 1199G>A and 3435C>T). Also, no differences
between the groups were observed in tacrolimus doses, unadjusted-
and dose-adjusted tacrolimus concentrations 3 months post-
transplantation (P > 0.05; Table S3 and S4 in the Supporting Informa-
tion). The [Tac]cells/[Tac]blood ratio was numerically, but not signifi-
cantly, higher in the 3435T allele carriers compared to non-carriers at
Month 3 (median 3.9 (IQR 2.5–5.5) vs. 3.1 (IQR 2.2–4.0); P = 0.06). At
Months 6 and 12 post-transplantation, no differences in [Tac]cells/
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[Tac]blood ratios were present between the different genotypes. More-
over, [Tac]cells/dose was not significantly different in 3435T carriers
compared to non-carriers (median 4.6 (IQR 2.9–8.4) vs. 5.3 (IQR 3.7–
6.4); P = 0.96).
Also when ABCB1 1199G>A and 3435C>T genotypes were
pooled, no significant differences were observed in either the (dose-
corrected) [Tac]cells, [Tac]blood, nor the [Tac]cells/[Tac]blood ratio
between patients without allelic variants, those carrying one variant
and those harbouring more than one variant in the ABCB1 genes
(Table 2).
3.4.2 | CYP3A metabolic phenotype
CYP3A4 and CYP3A5 genotypes were combined to classify patients as
poor, intermediate and extensive CYP3A metabolizers. The CYP3A
metabolic phenotype was associated with tacrolimus concentrations
(Table 3). Three months post-transplantation, the tacrolimus dose was
significantly different between poor, intermediate and extensive
metabolizers (median 3.0 mg (IQR 2.8–5.5) vs. 5.0 mg (IQR 4.0–6.0)
vs. 10.0 mg (IQR 9.0–12.0) respectively; P < 0.001). In addition, the
dose-adjusted [Tac]blood was significantly different between these
groups (median 2.3 (IQR 1.7–3.1) vs. 1.6 (IQR 1.1–2.1) vs. 0.7 (IQR
0.5–0.9) respectively, P < 0.001). Also, the dose-adjusted [Tac]cells was
significantly higher in poor and intermediate metabolizers, compared
to extensive metabolizers (median 7.3 (IQR 4.9–8.3) vs. 5.3 (IQR
3.6–8.8) vs. 2.4 (IQR 1.3–3.6), respectively, P < 0.001). The unadjusted
[Tac]cells and [Tac]blood were not significantly associated with CYP3A
TABLE 1 Baseline characteristics
n = 175









Body weight (kg) 80.9 (IQR 69.4–92.3)
Height (cm) 174.5 (IQR 166.3–182.0)
BMI (kg/m2) 25.9 (IQR 23.7–29.6)
Primary kidney disease
Diabetic nephropathy 31 (17.7%)
Polycystic kidney disease 34 (19.4%)
Glomerulonephritis 8 (4.6%)
Hypertensive nephropathy 30 (17.1%)
Reflux disease/chronic pyelonephritis 12 (6.9%)
Focal segmental glomerulosclerosis 5 (2.9%)
IgA nephropathy 8 (4.6%)
Obstructive nephropathy 7 (4.0%)
Other 23 (13.1%)
Unknown 17 (9.7%)










Serum creatinine (Month 3; μmol/L) 125.0 (104.2–150.8)
Haematocrit (Month 3; L/L) 0.37 (0.34–0.40)
Serum albumin (Month 3; g/L) 46.0 (44.0–48.0)




F IGURE 1 Scatter plots illustrating the distribution of whole-
blood and PBMC tacrolimus concentrations in the 3rd (A), 6th (B) and
12th (C) month after transplantation with Spearman's correlation
coefficient
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metabolizing status. The [Tac]cells/[Tac]blood ratio was significantly dif-
ferent between the groups at Month 6 post-transplantation (median
2.3 (IQR 1.9–2.9) vs. 3.6 (IQR 2.5–5.1) vs. 3.9 (IQR 2.6–5.8); P = 0.02).
Pairwise testing revealed a significant difference only between poor
and intermediate metabolizers.
3.5 | Covariate factors determining the PBMC to
whole-blood tacrolimus concentration ratio
In a multiple linear regression analysis, age and albumin were positive
predictors for the [Tac]cells/[Tac]blood ratio (β = 0.0229, P = 0.048;
β = 0.1275, P = 0.007, respectively), whereas haematocrit was a nega-
tive predictor for the [Tac]cells/[Tac]blood ratio (β = −16.138, P < 0.001;
Table 4).
The effect of changes in these predictors on the median [Tac]cells/
[Tac]blood ratio was estimated to evaluate clinical relevance. A 10-year
increase in age would result in a 0.23 higher [Tac]cells/[Tac]blood ratio.
Considering the median of 3.5 pg/106 cells per ng/mL as baseline
[Tac]cells/[Tac]blood ratio, this would correspond with an increase in
the ratio of 6.6%. A 5.0 g/L increase in albumin (i.e. from 45.0 to
50.0 g/L) would increase the [Tac]cells/[Tac]blood ratio by 0.64,
corresponding to an increase of 18.2% of the median ratio. A 0.1 L/L
increase in haematocrit (i.e. from 0.35 to 0.45 L/L) would result in a
decrease in the [Tac]cells/[Tac]blood ratio of 1.61, which corresponds to
a decrease of 46.1% in the ratio.
3.6 | Tacrolimus concentrations and clinical
outcomes
3.6.1 | Rejection
Fourteen out of 175 patients (8.0%) developed BPAR within the first
three postoperative months. Five patients (2.9%) were diagnosed with
a borderline rejection and in three patients (1.7%) a rejection episode
was presumed (i.e. treated but not histologically confirmed). The other
153 patients remained rejection free. No statistically significant differ-
ences were observed between patients with and without BPAR in
either [Tac]cells (median 24.8 pg/10
6 cells (IQR 18.4–34.8) vs.
27.0 pg/106 cells (IQR 19.0–37.0); P = 0.54), [Tac]blood (median
7.0 ng/mL (IQR 4.9–8.3) vs. 7.7 ng/mL (IQR 6.4–9.2); P = 0.18) or the
[Tac]cells/[Tac]blood ratio (median 3.8 (IQR 2.4–5.6) vs. 3.5 (IQR 2.4–
4.9); P = 0.67; Table 5). In a regression analysis, the [Tac]cells/[Tac]blood
ratio was not a significant predictor for rejection occurring within the
first 3 months after transplantation, when corrected for age, current
and highest PRA, and total HLA mismatches (Table S5 in the
Supporting Information).
3.6.2 | Tacrolimus-related toxicity
Fifty-two (29.7%) patients suffered from tacrolimus-related nephro-
toxicity within the first 3 months post-transplantation. No significant
differences existed in [Tac]blood (median 7.3 ng/mL (IQR 5.8–8.4) vs.
7.8 ng/mL (IQR 6.2–9.2); P = 0.38) or [Tac]cells (median 26.5 pg/10
6
cells (IQR 20.3–33.6) vs. 27.0 pg/106 cells (IQR 18.3–38.3); P = 0.91)
between recipients with or without nephrotoxicity. No significant dif-
ference was found in the [Tac]cells/[Tac]blood ratio at the third postop-
erative month (median 3.6 (IQR 2.7–5.4) vs. 3.5 (IQR 2.4–5.1);
P = 0.60; Table 5).
Thirty-six (20.6%) patients were diagnosed with PTDM within
the first 3 months after kidney transplantation. No significant differ-
ences were observed between patients with and without PTDM in
[Tac]blood (median 7.0 ng/mL (IQR 6.0–8.9) vs. 7.6 ng/mL (IQR 6.2–
9.2); P = 0.26), [Tac]cells (median 28.0 pg/10
6 cells (IQR 20.1–38.8)
vs. 26.5 pg/106 cells (IQR 18.5–36.5); P = 0.58) or the [Tac]cells/
[Tac]blood ratio (median 4.0 (IQR 2.7–5.9) vs. 3.5 (IQR 2.4–5.0);
P = 0.26; Table 5). In regression analysis, the [Tac]cells/[Tac]blood
ratio was not a significant predictor for either drug-related
(A)
(B)
F IGURE 2 Spaghetti plot (on a logarithmic scale; A) and a boxplot
(B) illustrating the evolution of the tacrolimus PBMC to whole-blood
ratio together with its median 3, 6 and 12 months after
transplantation
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nephrotoxicity (univariate) or PTDM (corrected for age, BMI and
creatinine) 3 months post-transplantation (Tables S6 and S7 in the
Supporting Information).
4 | DISCUSSION
In this study, 175 patients were prospectively followed to evaluate
tacrolimus PBMC concentrations after kidney transplantation. The
relationship between [Tac]cells and [Tac]blood was poor to moderate.
Age, albumin and haematocrit were associated with the [Tac]cells/
[Tac]blood ratio, whereas pharmacogenetic variability was not. Three
months post-transplantation, this ratio was not associated with clinical
outcomes.
The poor to moderate correlation between [Tac]cells and [Tac]blood
after solid organ transplantation has been reported by other research
groups.8,11,13–17 In kidney transplant recipients with a stable kidney
function, a moderate correlation between [Tac]cells and [Tac]blood was
observed (r = 0.67), which corresponds to the observation in the pre-
sent study.11 The poor correlation might be explained by factors
affecting the tacrolimus distribution and indicates that [Tac]blood does
not properly reflect the [Tac]cells. Under the assumption that the
tacrolimus concentration at the target site correlates better with its
immunosuppressive effect (which remains, however, to be
TABLE 2 The association between pooled ABCB1 1199G>A and 3435C>T genotype and tacrolimus concentrations
ABCB1 genotype Wildtype One variant allele >One variant allele P-value
Month 3 (n = 37) (n = 79) (n = 51)
Dose (mg) 5.0 (4.0–7.0) 6.0 (4.0–8.0) 6.0 (4.0–9.0) 0.48
[Tac]blood (ng/mL) 7.8 (6.4–9.0) 7.5 (6.0–9.6) 7.3 (5.9–8.6) 0.65
[Tac]blood/dose 1.7 (0.9–2.1) 1.5 (0.8–2.1) 1.3 (0.8–1.9) 0.33
[Tac]cells (pg/10
6 cells) 24.5 (16.0–33.0) 27.0 (19.5–40.5) 28.5 (19.8–35.8) 0.29
[Tac] cells/dose 5.3 (3.7–6.4) 4.6 (3.0–8.7) 4.5 (2.8–7.3) 0.68
[Tac]cells/[Tac]blood 3.1 (1.8–4.0) 3.9 (2.8–5.4) 3.6 (2.4–5.6) 0.12
Month 6 (n = 29) (n = 61) (n = 35)
[Tac]cells/[Tac]blood 3.5 (2.4–4.3) 3.4 (2.4–5.4) 3.7 (2.5–5.1) 0.72
Month 12 (n = 15) (n = 17) (n = 20)
[Tac]cells/[Tac]blood 3.8 (2.7–4.4) 3.6 (2.9–4.3) 3.3 (2.4–5.6) 0.99
[Tac]cells indicates the unadjusted tacrolimus pre-dose concentration in peripheral blood mononuclear cell concentration. [Tac]blood indicates the
unadjusted tacrolimus pre-dose whole blood concentration. Data is shown as median (IQR). P denotes the comparison between groups by Kruskal-
Wallis test.
TABLE 3 Poor, intermediate and extensive metabolizers and the association with tacrolimus concentrations
Metabolizers Poor Intermediate Extensive P-value
Month 3 (n = 16) (n = 117) (n = 33)
Dose (mg) 3.0 (2.8–5.5)b 5.0 (4.0–6.0)c 10.0 (9.0–12.0)b,c <0.001
[Tac]blood (ng/mL) 8.2 (7.0–9.8) 7.5 (6.1–9.0) 7.5 (6.1–9.2) 0.59
[Tac]blood/dose 2.3 (1.7–3.1)
a,b 1.6 (1.1–2.1)a,c 0.7 (0.5–0.9)b,c <0.001
[Tac]cells (pg/10
6 cells) 25.3 (18.8–29.6) 27.5 (19.0–37.0) 24.0 (17.5–34.5) 0.47
[Tac]cells/dose 7.3 (4.9–8.3)
b 5.3 (3.6–8.8)c 2.4 (1.3–3.6)b,c <0.001
[Tac]cells/[Tac]blood 3.0 (2.5–4.3) 3.8 (2.6–5.6) 3.5 (2.1–4.2) 0.25
Month 6 (n = 14) (n = 83) (n = 25)
[Tac]cells/[Tac]blood 2.3 (1.9–2.9)
a 3.6 (2.5–5.1)a 3.9 (2.6–5.8) 0.02
Month 12 (n = 6) (n = 36) (n = 9)
[Tac]cells/[Tac]blood 3.6 (2.9–4.3) 3.6 (2.4–4.6) 3.6 (2.9–5.8) 0.91
[Tac]cells indicates the unadjusted tacrolimus pre-dose concentration in peripheral blood mononuclear cell concentration. [Tac]blood indicates the
unadjusted tacrolimus pre-dose whole blood concentration. Data is shown as median (IQR). P denotes the comparison between groups by Kruskal-
Wallis test.
aP < 0.05 comparing poor metabolizers to intermediate metabolizers with Bonferroni correction.
bP < 0.05 comparing poor metabolizers to extensive metabolizers with Bonferroni correction.
cP < 0.05 comparing intermediate metabolizers to extensive metabolizers with Bonferroni correction.
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demonstrated), a poor correlation can explain why [Tac]blood predicts
clinical outcomes poorly. Monitoring the [Tac]cells has therefore been
proposed as a more meaningful matrix.12 Interestingly, the relation-
ship between [Tac]cells and [Tac]blood seemed to improve with time
after transplantation in the present study. However, this may have
been caused by the decreasing number of available tacrolimus mea-
surements over time.
The [Tac]cells/[Tac]blood ratio appeared to be stable in most
patients (median CV 39.0%). This observation is in line with the obser-
vations of Klaasen et al., who found a median CV of 45% in the
[Tac]cells/[Tac]blood ratios measured at 1 week, 6 weeks and 1 year
after renal transplantation.13 Inter-patient variability was higher than
the intra-patient variability, suggesting that an individual's ratio might
be useful in the prediction of future tacrolimus ratios and dose
requirements.
Inter- and intra-patient variability in the tacrolimus distribution
might be explained by covariate factors. Covariate factors known to
affect the [Tac]cells/[Tac]blood ratio allow the identification of patients
at risk for extremely high or low ratios. These patients might have a
higher risk for adverse clinical outcomes. In the present study, age and
albumin were positive predictors and haematocrit was a negative pre-
dictor for the [Tac]cells/[Tac]blood ratio. In whole-blood, tacrolimus is
highly bound to erythrocytes. A higher haematocrit may therefore
reflect a higher tacrolimus binding capacity, which limits the shift of
tacrolimus to the intracellular compartment and decreases the
[Tac]cells/[Tac]blood ratio. Age has been associated with lower
tacrolimus metabolism and dose requirement.36 The present results
suggest that age is also involved in the distribution of tacrolimus,
although the effect of a one-year increase in age on the [Tac]cells/
[Tac]blood ratio was limited (0.02 per year). The positive correlation
between albumin and the [Tac]cells/[Tac]blood ratio is not easily
explained. Theoretically, a higher albumin concentration might be
expected to increase tacrolimus binding, resulting in a decrease in the
[Tac]cells/[Tac]blood ratio. As reduced serum albumin concentrations
have been associated with inflammation (which occurs frequently in
transplant recipients), an explanation for the positive relationship
might be underlying inflammatory disease.37,38 Inflammation has been
associated with lower albumin concentrations and reduced CYP3A
activity.39,40 Lower CYP3A activity might in turn lower the [Tac]cells/
[Tac]blood ratio. Factors that were previously associated with the
tacrolimus distribution are ABCB1 genotype, total plasma protein con-
centration, sex, haematocrit and time after transplantation.11,18
SNPs in the ABCB1 gene have been associated with reduced
activity of this efflux transporter,41,42 which might affect the distribu-
tion of tacrolimus.20 In the present study, both ABCB1 1199G>A and
3435C>T genotypes were not associated with [Tac]cells or the
[Tac]cells/[Tac]blood ratio. The [Tac]cells/[Tac]blood ratio was, at Month
3, numerically, but not significantly higher in 3435T allele carriers
TABLE 4 Multivariable linear regression PBMC to whole-blood
tacrolimus concentration ratio
Dependent variable β SE P-value
(Intercept) 2.000 2.578
Age 0.0229 0.0115 0.048
Gender (female) −0.4003 0.4011 0.320
ABCB1 (one variant) 0.7236 0.4105 0.080
ABCB1 (>one variant) 0.7988 0.4482 0.077
CYP3A (poor) 0.0101 0.6363 0.987
CYP3A4 (intermediate) 0.6405 0.3798 0.094
Serum albumin 0.1275 0.0463 0.007
Serum creatinine −0.0011 0.0046 0.813
Haematocrit −16.138 4.070 0.0001
TABLE 5 Tacrolimus concentrations and clinical outcomes at Month 3 post-transplantation
Yes No P-value
BPAR (n = 14) (n = 153)
[Tac]blood (ng/ml) 7.0 (4.9–8.3) 7.7 (6.4–9.2) 0.18
[Tac]cells (pg/10
6 cells) 24.8 (18.4–34.8) 27.0 (19.0–37.0) 0.54
[Tac]cells/[Tac]blood 3.8 (2.4–5.6) 3.5 (2.4–4.9) 0.67
Nephrotoxicity (n = 52) (n = 123)
[Tac]blood (ng/ml) 7.3 (5.8–8.4) 7.8 (6.2–9.2) 0.38
[Tac]cells (pg/10
6 cells) 26.5 (20.3–33.6) 27.0 (18.3–38.3) 0.91
[Tac]cells/[Tac]blood 3.6 (2.7–5.4) 3.5 (2.4–5.1) 0.60
PTDM (n = 36) (n = 139)
[Tac]blood (ng/ml) 7.0 (6.0–8.9) 7.6 (6.2–9.2) 0.26
[Tac]cells (pg/10
6 cells) 28.0 (20.1–38.8) 26.5 (18.5–36.5) 0.58
[Tac]cells/[Tac]blood 4.0 (2.7–5.9) 3.5 (2.4–5.0) 0.26
[Tac]cells indicates the unadjusted tacrolimus pre-dose concentration in peripheral blood mononuclear cell concentration. [Tac]blood indicates the
unadjusted tacrolimus pre-dose whole blood concentration. Data is shown as median (IQR). P denotes the comparison by the Mann–Whitney U-test.
BPAR, biopsy-proven acute rejection; PTDM, post-transplant diabetes mellitus.
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compared to non-carriers. Also ABCB1 1199G>A and 3435C>T geno-
type combined was not predictive for the [Tac]cells/[Tac]blood ratio.
Previous research on the importance of different ABCB1 SNPs for the
tacrolimus distribution in solid organ transplant recipients was incon-
clusive. A study in 214 kidney transplant recipients with a stable graft
function also found that ABCB1 genotype (including 3435C>T) was
not a significant predictor for the [Tac]cells/[Tac]blood ratio.
11 In con-
trast, in a study including 96 renal transplant recipients, ABCB1 geno-
type was a positive predictor for the [Tac]cells/[Tac]blood ratio 7 days
post-transplantation and [Tac]cells was strongly associated with ABCB1
genotype (including both 3435C>T and 1199G>A).18 In 32 liver trans-
plant recipients, Tron et al. found an association between ABCB1
1199G>A and [Tac]cells, but not between ABCB1 3435C>T genotypes
and [Tac]cells.
17 In a study in 150 liver transplant recipients, Elens et al.
found that ABCB1 (1199G>A and 2677G>T/A) genotype significantly
influenced hepatic tissue tacrolimus concentrations, whereas the
impact of ABCB1 on [Tac]blood was negligible.
43
Tacrolimus is extensively metabolized by CYP3A
enzymes.21,24,44,45 In this study, we confirm the importance of CYP3A
polymorphisms for tacrolimus dose requirement. CYP3A4 and CYP3A5
genotype combined (as poor, intermediate and extensive
metabolizers) was significantly associated with tacrolimus dose
requirement as well as [Tac]cells and [Tac]blood. The [Tac]cells/[Tac]blood
ratio was not significantly different between these groups. Our results
indicate that CYP3A-related tacrolimus metabolism affects both dose-
corrected [Tac]cells and [Tac]blood, but not the distribution of
tacrolimus. Capron et al. observed lower dose-adjusted [Tac]cells in
CYP3A5 expressers compared to non-expressers, which is in line with
the present results.18 In 32 liver transplant recipients, no difference in
either [Tac]cells or [Tac]blood (not dose-corrected) between different
CYP3A4 and CYP3A5 genotypes was found.17
Although the use of tacrolimus and TDM has greatly improved
transplant outcomes, the relationship between [Tac]blood and clinical
outcomes is still unclear. Multiple studies, including a meta-analysis
including 1304 patients, showed no correlation between tacrolimus
exposure and clinical outcomes.3,7,8 In everyday clinical practice,
rejection and drug-related toxicity still occur despite [Tac]blood being
within the tacrolimus target pre-dose concentration. Also, in a time-
to-event analysis, longitudinal exposure to tacrolimus was not associ-
ated with a composite clinical endpoint (including rejection, cytomega-
lovirus infection and death).9 Therefore, it was hoped that monitoring
tacrolimus concentrations at the target site would better correlate
with drug efficacy and clinical outcomes.10,12 In the present study, no
associations were observed between [Tac]cells, [Tac]blood or the
[Tac]cells/[Tac]blood ratio and either the risk of BPAR, tacrolimus-
related nephrotoxicity or PTDM at the third postoperative month.
This might be (in part) explained by the fact that intracellular
tacrolimus concentrations were measured at a fixed time point, which
was often different from the moment of diagnosis. To overcome this
shortcoming, in an ongoing prospective trial performed by our
research group, (intracellular) tacrolimus concentrations are measured
on the morning of a for-cause renal biopsy. Another explanation for
the lack of associations between tacrolimus concentrations and
clinical outcomes is the variability in the tacrolimus concentration
measurement, due to the use of immunoassays instead of the more
sensitive LC–MS/MS method or red blood cell contamination. Also
the use of TDM might in part explain the lack of correlation, as alter-
native tacrolimus concentrations are necessary to be able to show an
association with clinical outcomes. Finally, it is possible that both
whole-blood and intracellular tacrolimus concentrations are not the
right matrix for monitoring tacrolimus exposure. Future studies may
also focus on other matrices to monitor tacrolimus treatment, which
might have a stronger correlation with clinical outcomes, such as for
example, the T lymphocyte subset of PBMCs or the unbound (or free)
tacrolimus concentrations.2,46–48
Previous studies evaluated the association between [Tac]cells and
drug efficacy but results are contradictory. In 213 kidney transplant
recipients, [Tac]cells was associated with T cell activation,
11 whereas in
10 liver transplant recipients no association between [Tac]cells and cal-
cineurin activity was found.49 Interestingly, in the latter study, the one
patient that experienced rejection (despite adequate [Tac]blood), had
area-under the PBMC concentration–time curves (AUCs) that were
four times lower than the mean AUCs of the other patients. The dif-
ferences in the association between [Tac]cells and T cell function might
be explained by the difference in sample size, as the last study may
have been underpowered. In 90 liver transplant recipients on
tacrolimus mono-therapy, [Tac]cells significantly correlated with both
the development and the severity of rejection.8 Lower tacrolimus
[Tac]cells was associated with higher histological grades of rejection,
while rejection grade was not associated with [Tac]blood. However,
these results have never been replicated. Klaasen et al. did not find
any significant differences in [Tac]cells in kidney transplant recipients
with and without (sub)clinical rejection.13 These conflicting results
might be explained by differences in transplanted organs (liver vs. kid-
ney), co-medication (tacrolimus mono-therapy vs. a combination of
basiliximab induction therapy, glucocorticoids and MMF), and time
post-transplantation (1–7 days vs. 1 week–1 year post-transplanta-
tion), as these factors associated with tacrolimus pharmacokinetics
and/or the risk of rejection. In the present study, the ABCB1 genotype
of the donor was not evaluated, which may be more relevant to the
development of CNI-related nephrotoxicity than the recipient
genotype.50–52
This prospective study included a large number of patients in
whom both an intracellular tacrolimus concentration was measured as
well as genotyping for CYP3A4, CYP3A5 and ABCB1 was performed.
Moreover, the data quality from the present analysis is high, as these
data were collected as part of a randomized, controlled clinical trial. A
limitation of the present analysis is that [Tac]blood was measured with
immunoassays. This relates to the fact that this was a post hoc analysis
of a randomized, controlled clinical trial and that at that time
tacrolimus was not routinely measured with more sensitive tech-
niques such as LC–MS/MS. Second, [Tac]cells measurement can also
be affected by the presence of erythrocytes. In the present analysis,
samples were excluded from the analysis based on visual red level of
the cell pellets, as at the time of PBMC isolation it was not yet known
that red blood cells can affect the measurement of [Tac]cells. However,
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in future studies it is recommended to add a red-blood cell lysis
step.30 Also, a high number of missing values was observed, especially
at 12 months post-transplantation, which can be explained by the
fewer hospital appointments with increasing time after transplanta-
tion. Since most endpoints concerned data from the first three post-
operative months, the effect on the conclusions are expected to be
limited. Another limitation of the study design that might explain why
no association between tacrolimus concentrations and clinical out-
comes was found, is the fact that samples were collected at a fixed
time-point (Month 3), whereas rejection or drug-related toxicity could
be diagnosed at any time-point during the first three post-transplant
months (biopsies were performed for cause only). Both [Tac]cells and
[Tac]blood may have changed after diagnosis due to pharmacokinetic
changes or dose adaptations by the attending physicians. Future stud-
ies should therefore investigate [Tac]cells at the time of a for-cause
biopsy, when protocol biopsies are taken or at the time of clinical
diagnosis of an adverse event.
5 | CONCLUSION
In conclusion, in this prospective study including 175 renal trans-
plant recipients, a poor correlation between [Tac]cells and [Tac]blood
was observed, although this correlation seemed to improve with
time after transplantation. The tacrolimus distribution over PBMC
and whole-blood appears to be relatively stable over time in individ-
ual patients. Predictors for the [Tac]cells/[Tac]blood ratio were age,
albumin and haematocrit, whereas ABCB1 genotype was not signifi-
cantly related to tacrolimus distribution. CYP3A genotype affects
both dose-corrected [Tac]cells and [Tac]blood, but not the tacrolimus
distribution. [Tac]cells did not correlate with clinical outcomes
3 months post-transplantation. Based on the outcomes of this
study, it is not recommended to implement monitoring of [Tac]cells
as they were not more predictive of clinical outcome than whole-
blood concentrations.
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